MicroVue™ TRAP5b EIA

The MicroVue TRAP5b Assay is an immunocapture enzyme assay for the determination of tartrate-resistant acid phosphatase isoform 5b (TRAcP 5b) in human serum and plasma.


Product Specifications

Citations 11
Specimen

Serum/Heparin Plasma 50 μL

LLOQ N/A
ULOQ N/A
Assay Time 2 hours
Cross Reactivity

None

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number 8033
Catalog Number (CE) 8036
Size 96 wells/test
Price (USD) $970.00
Price (EURO) 680,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

The MicroVue TRAP5b Assay is an immunocapture enzyme assay for the determination of tartrate-resistant acid phosphatase isoform 5b (TRAcP 5b) in human serum and plasma.

Size 96 wells/test
Form

96 well plate with murine monoclonal anti-TRAP5b antibodies

Specimen Serum/Heparin Plasma 50 μL
Limit of Detection (LOD) 0.24 U/L
Lower Limit of Quantitation (LLOQ) N/A
Upper Limit of Quantitation (ULOQ) N/A
Intra Assay 1.9–2.2%
Inter Assay 2.0–3.0%
Standards 5
Controls 2
Sample Values

Females (Ages 30–44) (premenopausal) 2.9±1.4 U/L or (Ages ≥50) (postmenopausal) 4.3±1.5 U/L, Males (Ages ≥20) 4.0±1.4 U/L

Assay Time 2 hours
Cross Reactivity

None

Storage

Store unopened kit between 2°C to 8°C. Refer to manual for storing individual components

Background

TRAP5b (serum band 5 tartrate-resistant acid phosphatase, TRAcP 5b; EC 3.1.3.2) is a 35-37 kDa glycoprotein. TRAP5b is typically expressed in proportion to osteoclast activity and is secreted into circulation. As a result, serum TRAP5b is considered a potentially useful marker for bone resorption. The MicroVue TRAP5b EIA detects the enzyme activity of bound TRAP5b in experimental samples.

Citations

Title Year Applications Sample Species Sample Sample Details

Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin.

2012

ELISA

Human

Serum

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.

2012

ELISA

Human

Multiple Myeloma cells

A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells.

2013

ELISA

Human

Monocytes

Different health behaviours and clinical factors associated with bone mineral density and bone turnover in premenopausal women with and without type 1 diabetes.

2015

ELISA

Human

Serum

Premenopausal Women w/wo Type 1 Diabetes

Effects of an 8-Month Ashtanga-Based Yoga Intervention on Bone Metabolism in Middle-Aged Premenopausal Women: A Randomized Controlled Study.

2015

ELISA

Human

Serum

Middle-Aged Premenopausal Women

Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis.

2017

ELISA

Human

Serum

Clinical and Biological Signature of Osteochondritis Dissecans in a Cross-Sectional Study.

2019

ELISA

Human

Serum

Osteochondritis Dissecans

Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers.

2019

ELISA

Human

Serum

Chronic Kidney Disease

Interferon Gamma-1b Does Not Increase Markers of Bone Resorption in Autosomal Dominant Osteopetrosis.

2019

ELISA

Human

Serum

Albers- Schönberg disease

Comprehensive assessment of tissue and serum parameters of bone metabolism in a series of orthopaedic patients.

2019

ELISA

Human

Serum

Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model.

2011

ELISA

Mouse

Serum